{"uid":"cap_4-SgnjFe7uPx33YQ0OwKl","slug":"ema-human-medicines-search-2fca9b9c","name":"EMA Human Medicines Search","description":"European Medicines Agency (EMA) centrally authorised human medicines (EMA bulk JSON, updated twice a day): name, EMA product number, status, active substance, ATC code, therapeutic indication, first authorisation date and holder. Searches name or active substance. Up to 20 per call.","url":"https://api.healthtravel-api.workers.dev/api/health/ema-human-medicines?utm_source=zero.xyz","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET"],"type":"string"},"queryParams":{"type":"object","required":["q"],"properties":{"q":{"type":"string","description":"Medicine name or active substance, letters, digits and spaces, 2 to 60 characters"},"max":{"type":"string","description":"How many medicines, 1 to 20 (default 5)"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query":"asparaginase","total":2,"source":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","dataAsOf":"2026-10-23T08:10:12.454Z","checkedAt":"2026-10-23T09:36:23.605Z","medicines":[{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/spectrila","name":"Spectrila","holder":"Medac Gesellschaft fuer klinische Spezialpraeparate mbH","status":"Authorised","atcCode":"L01XX02","category":"Human","indication":"Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.","productNumber":"EMEA/H/C/002661","activeSubstance":"asparaginase","authorisationDate":"14/01/2016"},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/graspa-0","name":"Graspa","holder":"ERYTECH Pharma S.A.","status":"Application withdrawn","atcCode":"LX1XX02","category":"Human","indication":"Treatment of acute lymphoblastic leukaemia","productNumber":"EMEA/H/C/004736","activeSubstance":"asparaginase","authorisationDate":"27/06/2018"}]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.002","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.002/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.002","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.002","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_6IdoqS06-FQb9wjHeG2cJ","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.002","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Search the European Medicines Agency (EMA) database for authorised human medicines by drug name or active substance, returning regulatory status, ATC code, indication, and marketing authorization details.","exampleAgentPrompt":"Can you search the EMA medicines database for 'asparaginase' and tell me which medicines are authorised, who holds the marketing authorisation, and what conditions they treat? Show me up to 5 results.","exampleUseCases":[{"title":"Checking European drug authorisation status","prompt":"Is imatinib authorised by the European Medicines Agency? I need the approval status, the authorisation holder, and what cancer types it's indicated for."},{"title":"Researching active substance approvals","prompt":"Search the EMA database for all medicines containing 'pembrolizumab' as the active substance — give me their names, statuses, and indications, up to 10 results."},{"title":"Regulatory due diligence on a withdrawn drug","prompt":"Look up 'valsartan' in the EMA human medicines database and tell me if any products have been withdrawn, who held the authorisation, and what the product numbers were."}],"resultDescription":"Returns a JSON object with the search query, total number of matching medicines, data source URL, data timestamp, and an array of medicine records. Each record includes the EMA medicine page URL, brand name, marketing authorisation holder, regulatory status (e.g. Authorised, Application withdrawn), ATC code, category, therapeutic indication, EMA product number, active substance, and authorisation date.","failureModes":["Query too short (under 2 characters) or too long (over 60 characters) returns a validation error","No medicines found for obscure or misspelled drug names returns empty results array","EMA source data temporarily unavailable may result in stale or failed fetch","Invalid 'max' parameter (outside 1-20 range) may cause error or default behaviour","Non-latin or special characters in query may yield no results"],"whenToPreferThis":"Use this endpoint when you need official EMA regulatory status, marketing authorisation details, or therapeutic indication data for human medicines in the European Union. Prefer this over national drug databases when EU-wide regulatory data is needed. Ideal for regulatory research, drug approval verification, or pharmacovigilance workflows where the EMA is the authoritative source.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-10-29T12:42:52.753Z","isFirstParty":false,"canonicalSlug":"ema-human-medicines-search-2fca9b9c"}